Oxurion NV
XBRU:OXUR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Oxurion NV
Long-Term Debt
Oxurion NV
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oxurion NV
XBRU:OXUR
|
Long-Term Debt
€2k
|
CAGR 3-Years
-93%
|
CAGR 5-Years
-71%
|
CAGR 10-Years
N/A
|
|
|
M
|
MDxHealth SA
NASDAQ:MDXH
|
Long-Term Debt
$84.7m
|
CAGR 3-Years
31%
|
CAGR 5-Years
47%
|
CAGR 10-Years
71%
|
|
|
Galapagos NV
AEX:GLPG
|
Long-Term Debt
€5.2m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Celyad Oncology SA
XBRU:CYAD
|
Long-Term Debt
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
European Medical Solutions
XBRU:ALEMS
|
Long-Term Debt
€11m
|
CAGR 3-Years
10%
|
CAGR 5-Years
105%
|
CAGR 10-Years
N/A
|
|
Oxurion NV
Glance View
Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Heverlee, Vlaams-Brabant and currently employs 42 full-time employees. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.
See Also
What is Oxurion NV's Long-Term Debt?
Long-Term Debt
2k
EUR
Based on the financial report for Jun 30, 2025, Oxurion NV's Long-Term Debt amounts to 2k EUR.
What is Oxurion NV's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
-71%
Over the last year, the Long-Term Debt growth was -94%. The average annual Long-Term Debt growth rates for Oxurion NV have been -93% over the past three years , -71% over the past five years .
